TradingView
The-Trend-is-the-Friend
Aug 7, 2022 8:53 PM

TEVA - Double Bottom? Long

Teva Pharmaceutical Industries LimitedNYSE

Description

TEVA has been a repair story now for many years. With litigation in the process of being resolved, debt burdens of $2 bn. per year appear manageable with cash flow - TEVA is moving away from a debt/litigation story
to an equity story. Cash Flow of 3bn + per year, Net Income of ~ 2bn.+.... warrant a blended Intrinsic Value of ~ $22 per share. TEVA's technicals show a textbook double bottom with positive divergence. Reverting to trends and fibonacci levels confirm $22 target.
Comments
redpilltrades
Even better, I think we did a triple bottom
DVM2Trader
Interesting. I took some 9/15 10C about a month ago after I noticed a large volume commons trade and unusual OI on the contract. Up 40% so far and I'm holding these until closer to Earnings.
More